Harness the power of flow cytometry to drive clinical trials forward

The critical role of flow cytometry in clinical trials assessing targeted therapies

Targeted therapies for use in clinical studies, such as those in immuno-oncology (I-O), are both the source of medical breakthroughs and the future of pharmaceuticals. Flow cytometry is a critical tool in employing these therapies, because it can assess the efficacy and safety of these molecules by giving us insight into how they interact with living cells on a cellular level.

Despite the availability of off-the-shelf flow cytometry assays, detecting the presence of complex molecules requires custom flow cytometric assays specific to these molecular targets. As a result, many sponsors do not have the resources required to develop customised assays in-house, requiring a partner with the expertise to consult the needs of their trial.

In our whitepaper, “Driving Clinical Trials Forward: The Benefits of Establishing a Strategic Partnership for Flow Cytometry,” we explore:

• Best practices in developing and implementing customised flow cytometric assays for clinical research
• The benefits of adopting a strategic partner in a CRO to perform these complex assays